HIGHLIGHTS
- who: Amber N. Edinoff and collaborators from the Department of Psychiatry, Massachusetts General Hospital, Harvard School of Medicine, Boston, MA, USA Department of Psychiatry and Behavioral Medicine, Louisiana State University Health Shreveport have published the article: Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects, in the Journal: (JOURNAL) of 30/09/2019
- what: This analysis determined that its main metabolic pathway is hydroxylation by CYP3A4 and CYP3A5, generating u03b1-hydroxy-flubromazolam and 4-hydroxy-flubromazolam as its predominant metabolites . The study showed a significant impairment in cognitive and psychomotor functions in all . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.